Armour Thyroid: Drug-Naive vs Treatment-Experienced Dosing for Women

What Is Armour Thyroid and Why the Drug-Naive vs Treatment-Experienced Distinction Matters

Armour Thyroid is a prescription natural desiccated thyroid (NDT) extract made from porcine thyroid glands. Each 60 mg (1 grain) tablet contains 38 mcg of levothyroxine (T4) and 9 mcg of liothyronine (T3). That fixed 4.2:1 T4-to-T3 ratio is higher in T3 relative to human thyroid output, which means every dosing decision carries a slightly different risk-benefit calculation than pure levothyroxine therapy.

The drug-naive vs treatment-experienced split matters because:

• A drug-naive patient has no current thyroid hormone exposure, so you are building from zero and the pituitary is not already suppressed.
• A treatment-experienced patient switching from levothyroxine already has circulating T4 (and some peripheral T3 conversion), so the transition requires overlap planning and a conversion ratio, not a ground-up titration.

Getting this wrong in either direction causes real harm. Under-replacement leaves you fatigued, anovulatory, or miscarrying. Over-replacement causes atrial fibrillation risk and bone loss, both concerns that compound in perimenopause and post-menopause.

Who Asks About Armour Thyroid?

Most women who inquire about Armour Thyroid fall into three groups: those newly diagnosed with hypothyroidism who want to avoid synthetic medication, those already on levothyroxine who feel persistently symptomatic despite normal TSH, and those with PCOS or autoimmune thyroid disease (Hashimoto thyroiditis) researching combination T4/T3 therapy. Approximately 5% of U.S. Adults have hypothyroidism, and women are 5 to 8 times more likely than men to be affected, making this a women's-health topic by epidemiology alone.

Sex-Specific Thyroid Physiology You Need to Know

Your thyroid hormone needs are not static. Estrogen raises thyroxine-binding globulin (TBG), which increases bound T4 and can drop free T4, which is why oral contraceptive users and pregnant women often need higher doses. Progesterone has a weak anti-estrogenic effect on TBG. TSH reference ranges shift across the menstrual cycle by a modest but measurable amount, which is one reason a single lab draw does not always tell the full story.

Drug-Naive Titration: Starting Armour Thyroid From Scratch

If you have never taken thyroid hormone replacement, the goal is to raise T4 and T3 gradually enough that your pituitary can re-calibrate and you avoid the adrenergic surge that high T3 causes when introduced too quickly.

The Starting Dose

The Armour Thyroid prescribing label recommends starting most adults at 30 mg (½ grain) daily. Some clinicians experienced with NDT start patients with significant fatigue or bradycardia at 15 mg (¼ grain) and titrate up over two weeks before the first formal increment. Both approaches are defensible; the ¼-grain start is gentler for women with any cardiac history or anxiety disorder.

Titration Schedule

| Week | Dose | What to Monitor | |------|------|-----------------| | Start | 30 mg (½ grain) | Baseline TSH, free T4, free T3, heart rate | | Week 4-6 | Increase to 60 mg (1 grain) if TSH still elevated | Symptoms, resting HR | | Week 10-12 | Increase to 90 mg (1.5 grain) if still under-replaced | Free T3 approaching upper half of range | | Week 16-18 | Increase to 120 mg (2 grain) if needed | TSH, free T3, free T4, bone density context if peri/post-menopausal | | Week 24 | Stabilization labs; annual monitoring thereafter | Full thyroid panel |

Most drug-naive women reach their maintenance dose between 60 mg and 120 mg daily. A smaller subset with severe autoimmune-driven destruction (Hashimoto) may need up to 180 mg. Doses above 120 mg should be split (morning and early afternoon) to smooth the T3 peak, because the half-life of T3 is only approximately 1 day compared to 7 days for T4.

What "Good Enough" Labs Look Like for a Drug-Naive Start

Target TSH of 0.5 to 2.5 mIU/L, free T4 in the mid-range, and free T3 in the upper half of your lab's reference range. A free T3 sitting in the lower third often means symptoms persist despite a "normal" TSH, which is the most common complaint women bring after 3 to 6 months on NDT.

Treatment-Experienced Titration: Switching From Levothyroxine to Armour Thyroid

This is the more common clinical scenario. A woman is on stable levothyroxine, TSH is in range, yet she continues to experience brain fog, fatigue, low libido, constipation, or cold intolerance. She asks about NDT.

Is There Evidence That Switching Helps?

The 2013 Hoang et al. RCT published in the Journal of Clinical Endocrinology and Metabolism compared desiccated thyroid extract to levothyroxine in 70 hypothyroid patients over one year. Participants on NDT lost an average of 0.9 kg more than those on levothyroxine and, at the end of the study, 48.6% preferred NDT vs 18.6% who preferred levothyroxine. TSH, free T4, free T3, and quality-of-life scores were similar between groups. Women made up the majority of the trial cohort.

A 2019 randomized crossover trial by Idrees et al. In the European Thyroid Journal found no significant difference in quality of life between NDT and levothyroxine but confirmed that a meaningful subgroup reported symptom preference for NDT. These are small trials. That limitation is real, and the evidence base here is genuinely thin, particularly for women across different life stages.

The Conversion Ratio

The commonly cited conversion is 60 mg of Armour Thyroid per 100 mcg of levothyroxine. In practice, most clinicians convert at 80 to 85% of the calculated equivalent dose on day one, then titrate up, because the added T3 in Armour Thyroid means even a "equivalent" paper dose can over-replace initially.

Example conversion:

• Current dose: Levothyroxine 100 mcg daily
• Calculated Armour equivalent: 60 mg (1 grain)
• Recommended starting Armour dose: 45 to 60 mg daily (checking labs at 4 to 6 weeks before increasing)

Switching Protocol Step by Step

1. Obtain baseline labs: TSH, free T4, free T3, and a thyroid peroxidase antibody if not done recently.
2. Stop levothyroxine. Do NOT taper levothyroxine while starting Armour. Overlap causes unpredictable TSH suppression.
3. Start Armour Thyroid at 80-85% of the calculated equivalent dose on day one.
4. Recheck labs at 4 to 6 weeks. If TSH is still elevated and free T3 is not at the upper half of range, increase by 15 to 30 mg.
5. Target stabilization by week 12 to 16 in most patients.
6. Split the dose if above 90 mg daily to reduce the mid-morning T3 peak.

The above "stop and start" protocol, rather than a cross-taper, is the approach most consistent with current NDT prescribing experience and the label guidance. A cross-taper (reducing levothyroxine while adding Armour Thyroid) is used by some integrative medicine clinicians but carries a higher risk of transient TSH elevation or suppression and makes it harder to interpret the 4-to-6-week labs.

How Your Life Stage Changes Everything

Reproductive Years (Ages 18-40)

If you have regular periods, watch for two things: thyroid dose adequacy often becomes apparent premenstrually, when symptoms can flare even with a normal TSH. Your dose may need a small premenstrual boost or it may signal under-replacement overall. TSH is slightly lower in the follicular phase than the luteal phase, meaning a single mid-cycle TSH may not capture your full picture.

Women with PCOS have a higher prevalence of Hashimoto thyroiditis compared to the general population, with some studies reporting subclinical hypothyroidism in 22-40% of women with PCOS. If you have PCOS and hypothyroidism, thyroid optimization should happen before or alongside any ovulation induction attempts.

Trying to Conceive (TTC)

This is the most critical life stage for thyroid management. The American Thyroid Association recommends a pre-conception TSH below 2.5 mIU/L for women planning pregnancy. That target is generally achievable on Armour Thyroid, but the next section explains why most specialists recommend switching to levothyroxine once pregnancy is confirmed or actively pursued.

Perimenopause

Perimenopause is a window where thyroid symptoms and perimenopausal symptoms overlap almost completely: fatigue, brain fog, irregular periods, heat intolerance, mood changes, and sleep disruption. TSH naturally trends slightly upward with age in women, meaning a woman whose TSH was 1.8 at age 38 may have a TSH of 3.2 at age 49 and still be told she is "normal." If you are perimenopausal and symptomatic, getting a free T3 alongside TSH is more informative than TSH alone.

Women on hormone therapy (HT) for menopause who also take Armour Thyroid need to know that oral estrogen raises TBG and increases demand for thyroid hormone. Oral estrogen can increase levothyroxine requirements by 25-50% in post-menopausal women, and a similar increase in NDT dose may be needed. Transdermal estrogen has a much smaller effect on TBG and typically does not require a dose adjustment.

Post-Menopause

Bone health is the primary concern here. Excess thyroid hormone suppresses TSH and accelerates bone turnover. Subclinical hyperthyroidism (TSH <0.1 mIU/L) is associated with a 3-fold increased risk of hip fracture in post-menopausal women. If you are post-menopausal and on Armour Thyroid, your TSH should stay at or above 0.5 mIU/L. Routine bone density monitoring (DEXA) every 2 years is reasonable on any thyroid hormone that approaches suppressive dosing.

Pregnancy and Lactation: What You Must Know Before Starting Armour Thyroid

Armour Thyroid is not recommended during pregnancy. This is not a minor caveat. The fixed T4:T3 ratio in NDT delivers more T3 than a human thyroid would naturally produce, and T3 crosses the placenta poorly. The developing fetus depends on maternal T4 for fetal brain development, particularly in the first trimester. ACOG and the Endocrine Society both recommend levothyroxine as the sole thyroid replacement agent in pregnancy, because dose adjustment is simpler, the pharmacokinetics are better characterized, and the evidence base is built entirely on levothyroxine data.

What to Do If You Are on Armour Thyroid and Become Pregnant

Switch to levothyroxine immediately. Do not wait for your next appointment. Use the conversion ratio (100 mcg levothyroxine per 60 mg Armour Thyroid) and get labs in 4 weeks. Pregnancy increases thyroid hormone demand by 30-50%, so your levothyroxine dose will almost certainly need to be higher than the conversion math alone suggests. A common approach is to increase the calculated dose by 30% on the day the pregnancy is confirmed.

Lactation

Levothyroxine and T3 are both present in breast milk in small amounts, but at physiologic levels that are generally considered safe. The American Academy of Pediatrics lists thyroid hormones as compatible with breastfeeding. If you were on Armour Thyroid before pregnancy, switched during pregnancy, and plan to return to NDT after delivery, you may safely do so after weaning or with your clinician's guidance during lactation. There is no published data on NDT specifically during lactation; the safety assumption is extrapolated from individual T4 and T3 lactation data.

Contraception Note

Armour Thyroid is not a teratogen in the classic sense, but inadequate thyroid replacement during pregnancy is directly associated with fetal neurodevelopmental harm, miscarriage, preterm birth, and preeclampsia. If you are on Armour Thyroid and not planning pregnancy, use reliable contraception and have a clear plan for switching to levothyroxine the moment a pregnancy test turns positive.

Who Is a Good Candidate for Armour Thyroid (and Who Is Not)

Good Candidates

• Women with persistent symptoms on adequate levothyroxine with normal TSH who want to try combination T4/T3 therapy
• Women with confirmed low free T3 despite normal TSH on levothyroxine (poor T4-to-T3 converters, sometimes linked to DIO2 gene variants)
• Women with Hashimoto thyroiditis who have discussed the benefits and limits of NDT with an endocrinologist or knowledgeable NP
• Post-menopausal women on transdermal (not oral) hormone therapy who prefer NDT and have baseline DEXA on file

Not Ideal Candidates

• Pregnant women or those actively trying to conceive (use levothyroxine)
• Women with atrial fibrillation, recent MI, or severe osteoporosis (the higher T3 load increases risk)
• Women who cannot tolerate dose variability (NDT is a natural product; lot-to-lot potency variation is a documented limitation)
• Women on oral estrogen therapy who are not prepared for more frequent dose adjustments
• Women with adrenal insufficiency that has not been addressed (high T3 can stress an already-taxed HPA axis)

Monitoring Schedule for Women on Armour Thyroid

| Time Point | Labs | Notes | |------------|------|-------| | Baseline | TSH, free T4, free T3, TPO-Ab, CBC, CMP | Rule out anemia, liver disease | | 4-6 weeks after any dose change | TSH, free T4, free T3 | Do not check sooner; TSH lags T3 changes | | Stabilization | Every 6 months x 1 year, then annually | Add DEXA if post-menopausal or on suppressive dose | | Pregnancy confirmed | Immediate switch to levothyroxine + labs in 4 weeks | Do not wait | | Starting oral estrogen/HT | Recheck in 6-8 weeks | TBG rises; NDT dose may need increase | | Stopping oral estrogen/HT | Recheck in 6-8 weeks | TBG falls; NDT dose may need decrease |

Practical Dosing Notes: Timing, Food, and Drug Interactions

Armour Thyroid should be taken on an empty stomach, 30 to 60 minutes before food, in the morning. If you split your dose (common above 90 mg), take the second portion no later than early afternoon to avoid sleep disruption from the T3 component. Calcium carbonate, iron supplements, and antacids containing aluminum can reduce absorption by up to 30-40% if taken within 4 hours of your thyroid dose.

Coffee reduces NDT absorption. Take your dose with plain water only. If you take biotin supplements, stop them 48 to 72 hours before any thyroid blood draw, because biotin interferes with the immunoassay and can falsely lower TSH or falsely raise free T4 and free T3, making your results appear as if you are over-replaced when you are not. The FDA issued a safety communication on biotin interference with lab tests in 2017.

The Evidence Gap: What We Do Not Know Yet for Women

Women have been the majority in most NDT trials, but none of those trials enrolled women stratified by menstrual cycle phase, hormonal contraception use, or menopausal status. The Hoang 2013 RCT had 70 participants total, a sample size where subgroup analyses for perimenopausal women would be meaningless. There are no large, prospective, women-specific NDT trials. Every dose recommendation above the starting dose is extrapolated from clinical experience, pharmacokinetic modeling, and small mixed-sex RCTs.

That is not a reason to avoid Armour Thyroid. It is a reason to monitor more closely than you might with a drug that has 50 years of large-trial data behind it, and to find a clinician who will treat your labs and symptoms together rather than relying on TSH alone.